About Makers Laboratories
Makers Laboratories is a publicly listed company based in Mumbai (India) founded in 1985. Branded generic pharmaceutical products are manufactured across multiple therapeutic segments. The company has 131 employees. Its Indian entity Makers Laboratories Ltd reported revenue of ₹142 Cr. Makers Laboratories offers products and services including Duramol and Artemak-AB. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.
Company details
Manufacturer of branded generic pharmaceutical products. It offers a portfolio covering various therapeutic segments, including antibiotics, cough and cold medications, cardio-diabetic treatments, anti-allergics, anthelmintics, and neurotonics. The company focuses on providing high-quality products at affordable prices. Its product line includes formulations such as paracetamol, arteether, chloroquine, nimuselide, and amoxycillin.
- Headquarters Mumbai, India
- Employees 131
- Stage Public
- SectorsHealthcare
- Website makerslabs.com
- Legal Name Makers Laboratories Ltd
- Market Cap₹110 Cr
MAKERSL · NSE
- Share Price₹187.00
+0.69% today
- Revenue₹141 Cr
FY 2025-26 · +16.4% YoY
- EBITDA₹14.82 Cr
Margin 10.5%
- Net Profit₹2.09 Cr
FY 2025-26 · +157.0% YoY
- P/E (TTM)32.3x
P/B 1.5x
- ROE11.0%
ROCE 14.9%
- Debt / Equity0.12
Interest cover 8.3x
- Employee Count131
Associated legal entities of Makers Laboratories
Makers Laboratories operates through Makers Laboratories Ltd, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Makers Laboratories Ltd Listed CIN L24230MH1984PLC033389 | Active | 09 Jul 1984 | Mumbai, Maharashtra | ₹142 Cr | 139 | 9 | View details |
Products & Services of Makers Laboratories
Makers Laboratories offers a comprehensive portfolio of products and services, including Duramol and Artemak-AB.
Paracetamol formulation is provided for general health applications
α-β Arteether formulation is supplied for therapeutic treatment
Board of directors of Makers Laboratories Ltd (Makers Laboratories)
Makers Laboratories Ltd is the primary company behind Makers Laboratories. The board of Makers Laboratories Ltd currently have 6 directors; the longest-serving is Saahil Umesh Parikh, appointed in 2012. 9 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Saahil Umesh Parikh DIN 00400079 | Whole-time director | 02 Aug 2012 | 14 yrs 2 mo | Makers Laboratories Ltd |
| Dipti Chinubhai Shah DIN 07995542 | Director | 29 Jan 2018 | 8 yrs 8 mo | Makers Laboratories Ltd |
| Raj Kamal Prasad Verma DIN 02166789 | Director | 13 Feb 2019 | 7 yrs 8 mo | Makers Laboratories Ltd |
| Nilesh Jain DIN 05263110 | Whole-time director | 13 Feb 2019 | 7 yrs 8 mo | Makers Laboratories Ltd |
| Prashant Godha DIN 00012759 | Director | 04 Nov 2020 | 5 yrs 11 mo | Makers Laboratories Ltd |
| Vishal Babulal Jain DIN 00137986 | Director | 04 Nov 2020 | 5 yrs 11 mo | Makers Laboratories Ltd |
IPO & Listings of Makers Laboratories
Makers Laboratories is a publicly listed company on the BSE with ticker symbol MAKERSL in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Jan 2002
- Listed onBSE: 506919
- Listed entityMakers Laboratories Ltd
- Exchange sectorHealth technology
- ISININE987A01010
- Share price₹154.95 (-1.15% on the day) · 2026-05-11
- Market capitalisation₹92.5 Cr
- Price to earnings75.4
- EPS (diluted, trailing year)₹2.06
- Volume (last session)2,555
- Analyst consensusNo rating
Financials of Makers Laboratories
Exchange-reported figures of Makers Laboratories Ltd, the listed company behind Makers Laboratories (NSE: MAKERSL).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 141 | 121 | 104 | 101 | 127 | 68.64 |
| Revenue growth | +16.4% | +15.7% | +3.1% | -20.4% | +85.3% | - |
| EBITDA | 14.82 | 7.60 | 1.12 | 3.33 | 18.82 | 8.12 |
| EBITDA margin | +10.5% | +6.3% | +1.1% | +3.3% | +14.8% | +11.8% |
| Profit before tax | 11.15 | 13.41 | (3.91) | (0.83) | 15.70 | 2.71 |
| Net profit | 2.09 | (3.67) | (6.29) | (4.76) | 4.97 | (0.42) |
| Net profit margin | +1.5% | -3.0% | -6.0% | -4.7% | +3.9% | -0.6% |
| EPS (₹) | 3.98 | 12.70 | (10.62) | (8.05) | 10.12 | (0.67) |
| Balance sheet | ||||||
| Total assets | 132 | 123 | 128 | 128 | 122 | 107 |
| Net worth | 72.92 | 70.51 | 63.05 | 69.20 | 59.58 | 54.13 |
| Total debt | 8.74 | 7.78 | 22.13 | 16.71 | 23.00 | 20.51 |
| Cash & bank | 0.63 | 0.65 | 2.23 | 4.37 | 8.67 | 6.22 |
| Net working capital | 48.05 | 51.44 | 41.26 | 46.31 | 48.27 | 39.95 |
| Cash flow | ||||||
| Cash from operations | 14.29 | (4.08) | 0.84 | (8.62) | 18.50 | 0.00 |
| Cash from investing | (14.69) | 19.75 | (6.89) | 1.25 | (21.79) | 0.00 |
| Cash from financing | 0.35 | (15.84) | 5.74 | 5.78 | 0.33 | 0.00 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 42.77 | 35.75 | 35.67 | 34.17 | 35.00 | 33.90 | 27.69 | 29.57 |
| Revenue growth (YoY) | +22.2% | +5.5% | +28.8% | +15.6% | +18.3% | - | - | - |
| Other income | 0.61 | 0.76 | 0.33 | 0.36 | 0.27 | 0.12 | 0.87 | 10.63 |
| EBITDA | 6.96 | 5.27 | 4.17 | 2.28 | 3.01 | 3.06 | 1.31 | 2.19 |
| EBITDA margin | +16.3% | +14.7% | +11.7% | +6.7% | +8.6% | +9.0% | +4.7% | +7.4% |
| Depreciation | 1.13 | 1.13 | 1.14 | 1.13 | 1.12 | 0.90 | 1.31 | 1.29 |
| Interest | 0.15 | 0.17 | 0.20 | 0.22 | 0.18 | 0.18 | 0.19 | 0.43 |
| Profit before tax | 6.29 | 4.73 | 3.16 | 1.29 | 1.98 | 2.10 | 0.68 | 11.10 |
| Tax | 1.70 | 1.18 | 0.88 | 0.55 | 0.69 | 0.52 | 0.41 | 1.33 |
| Net profit | 4.59 | 3.55 | 2.28 | 0.74 | 1.29 | 1.58 | 0.27 | 9.77 |
| EPS (₹) | 2.55 | 1.85 | 1.59 | (0.20) | 0.74 | (0.08) | (0.50) | 14.94 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 50.35 | 42.94 | 49.09 | 42.55 | 52.38 | 44.41 | 51.31 |
| Revenue growth | +17.3% | -12.5% | +15.4% | -18.8% | +18.0% | -13.5% | - |
| EBITDA | 0.73 | (2.21) | (3.76) | (4.12) | 3.07 | 3.31 | 2.73 |
| EBITDA margin | +1.5% | -5.2% | -7.7% | -9.7% | +5.9% | +7.5% | +5.3% |
| Profit before tax | (2.01) | 4.92 | (6.95) | (6.76) | 0.33 | (2.08) | 0.27 |
| Net profit | (1.73) | (5.76) | (6.97) | (6.36) | 0.23 | (1.79) | (0.10) |
| Net profit margin | -3.4% | -13.4% | -14.2% | -15.0% | +0.4% | -4.0% | -0.2% |
| EPS (₹) | (2.91) | 7.87 | (11.78) | (10.78) | 0.35 | (3.29) | (0.25) |
| Balance sheet | |||||||
| Total assets | 58.58 | 58.00 | 67.99 | 70.69 | 69.90 | 65.83 | 57.85 |
| Net worth | 54.43 | 56.08 | 51.45 | 58.28 | 50.30 | 49.62 | 44.62 |
| Total debt | 3.88 | 1.76 | 15.37 | 11.20 | 19.40 | 15.99 | 13.05 |
| Cash & bank | 0.03 | 0.04 | 0.07 | 0.08 | 0.14 | 0.34 | 0.96 |
| Net working capital | 5.29 | 3.16 | 2.89 | 5.26 | 6.40 | 10.39 | 9.42 |
| Cash flow | |||||||
| Cash from operations | (2.02) | (1.59) | (3.06) | (1.42) | 6.80 | 0.67 | 4.23 |
| Cash from investing | 0.28 | 16.14 | (2.04) | (3.55) | (8.78) | (2.65) | (8.43) |
| Cash from financing | 1.75 | (14.56) | 5.12 | 4.94 | 1.77 | 1.37 | 2.91 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.19 | 11.27 | 12.70 | 12.64 | 13.73 | 9.70 | 9.45 | 11.50 |
| Revenue growth (YoY) | -25.8% | +16.2% | +34.4% | +9.9% | +11.7% | - | - | - |
| Other income | 0.07 | 0.02 | 0.00 | 0.53 | 0.04 | 0.03 | 0.57 | 10.19 |
| Total expenses | 10.69 | 11.65 | 11.99 | 12.72 | 13.26 | 10.91 | 10.01 | 11.67 |
| EBITDA | (0.50) | (0.38) | 0.71 | (0.08) | 0.47 | (1.21) | (0.56) | (0.17) |
| EBITDA margin | -4.9% | -3.4% | +5.6% | -0.6% | +3.4% | -12.5% | -5.9% | -1.5% |
| Depreciation | 0.69 | 0.69 | 0.71 | 0.71 | 0.70 | 0.69 | 0.73 | 0.71 |
| Interest | 0.14 | 0.12 | 0.15 | 0.15 | 0.10 | 0.09 | 0.13 | 0.33 |
| Profit before tax | (1.26) | (1.17) | (0.15) | (0.41) | (0.29) | (1.96) | (0.85) | 8.98 |
| Tax | (0.18) | (0.20) | 0.03 | (0.10) | (0.03) | (0.57) | (0.08) | 0.95 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 42.77 | 35.75 | 35.67 | 34.17 | 35.00 | 33.90 | 27.69 | 29.57 |
| Revenue growth (YoY) | +22.2% | +5.5% | +28.8% | +15.6% | +18.3% | - | - | - |
| Other income | 0.61 | 0.76 | 0.33 | 0.36 | 0.27 | 0.12 | 0.87 | 10.63 |
| EBITDA | 6.96 | 5.27 | 4.17 | 2.28 | 3.01 | 3.06 | 1.31 | 2.19 |
| EBITDA margin | +16.3% | +14.7% | +11.7% | +6.7% | +8.6% | +9.0% | +4.7% | +7.4% |
| Depreciation | 1.13 | 1.13 | 1.14 | 1.13 | 1.12 | 0.90 | 1.31 | 1.29 |
| Interest | 0.15 | 0.17 | 0.20 | 0.22 | 0.18 | 0.18 | 0.19 | 0.43 |
| Profit before tax | 6.29 | 4.73 | 3.16 | 1.29 | 1.98 | 2.10 | 0.68 | 11.10 |
| Tax | 1.70 | 1.18 | 0.88 | 0.55 | 0.69 | 0.52 | 0.41 | 1.33 |
| Net profit | 4.59 | 3.55 | 2.28 | 0.74 | 1.29 | 1.58 | 0.27 | 9.77 |
| EPS (₹) | 2.55 | 1.85 | 1.59 | (0.20) | 0.74 | (0.08) | (0.50) | 14.94 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 141 | 121 | 104 | 101 | 127 | 68.64 |
| Revenue growth | +16.4% | +15.7% | +3.1% | -20.4% | +85.3% | - |
| Other income | 1.71 | 11.89 | 1.53 | 2.28 | 2.64 | 0.96 |
| Total expenses | 126 | 113 | 103 | 97.95 | 108 | 60.52 |
| Employee cost | 15.59 | 14.05 | 13.94 | 11.73 | 12.51 | 8.71 |
| EBITDA | 14.82 | 7.60 | 1.12 | 3.33 | 18.82 | 8.12 |
| EBITDA margin | +10.5% | +6.3% | +1.1% | +3.3% | +14.8% | +11.8% |
| Depreciation | 4.53 | 4.79 | 4.54 | 4.24 | 4.02 | 4.61 |
| Interest | 0.85 | 1.29 | 2.02 | 2.20 | 1.74 | 1.76 |
| Profit before tax | 11.15 | 13.41 | (3.91) | (0.83) | 15.70 | 2.71 |
| Tax | 3.29 | 2.51 | 0.89 | 1.35 | 3.97 | 1.36 |
| Net profit | 2.09 | (3.67) | (6.29) | (4.76) | 4.97 | (0.42) |
| Net profit margin | +1.5% | -3.0% | -6.0% | -4.7% | +3.9% | -0.6% |
| EPS (₹) | 3.98 | 12.70 | (10.62) | (8.05) | 10.12 | (0.67) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 5.90 | 5.90 | 5.90 | 5.90 | 4.92 | 4.92 |
| Reserves & surplus | 67.02 | 64.61 | 57.15 | 63.30 | 54.66 | 49.21 |
| Shareholders' funds (net worth) | 72.92 | 70.51 | 63.05 | 69.20 | 59.58 | 54.13 |
| Minority interest | 49.55 | 44.69 | 41.29 | 40.47 | 38.51 | 32.44 |
| Secured loans | 1.03 | 2.06 | 9.08 | 6.91 | 5.53 | 7.98 |
| Unsecured loans | 7.71 | 5.72 | 13.05 | 9.80 | 17.47 | 12.53 |
| Total debt | 8.74 | 7.78 | 22.13 | 16.71 | 23.00 | 20.51 |
| Total liabilities | 132 | 123 | 128 | 128 | 122 | 107 |
| Assets | ||||||
| Gross block | 120 | 119 | 136 | 130 | 110 | 81.94 |
| Net block | 70.54 | 74.16 | 86.56 | 84.53 | 68.30 | 71.39 |
| Capital work in progress | 3.73 | 0.59 | 0.32 | 0.49 | 9.38 | 0.16 |
| Investments | 11.73 | 0.14 | 2.93 | 0.08 | 0.22 | 1.97 |
| Inventories | 44.94 | 34.04 | 33.80 | 31.32 | 23.84 | 27.47 |
| Sundry debtors | 19.86 | 28.04 | 19.89 | 19.87 | 13.55 | 16.61 |
| Cash & bank balances | 0.63 | 0.65 | 2.23 | 4.37 | 8.67 | 6.22 |
| Loans & advances | 9.95 | 5.55 | 11.06 | 7.70 | 16.84 | 10.00 |
| Total current assets | 75.38 | 68.28 | 66.98 | 63.26 | 62.90 | 60.30 |
| Total current liabilities | 27.33 | 16.84 | 25.72 | 16.95 | 14.63 | 20.35 |
| Net working capital | 48.05 | 51.44 | 41.26 | 46.31 | 48.27 | 39.95 |
| Total assets | 132 | 123 | 128 | 128 | 122 | 107 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 0.24 | 0.41 | 0.72 | 2.31 | 5.27 | 0.00 |
| Net cash from operating activities | 14.29 | (4.08) | 0.84 | (8.62) | 18.50 | 0.00 |
| Net cash from investing activities | (14.69) | 19.75 | (6.89) | 1.25 | (21.79) | 0.00 |
| Net cash from financing activities | 0.35 | (15.84) | 5.74 | 5.78 | 0.33 | 0.00 |
| Net change in cash | (0.05) | (0.17) | (0.31) | (1.59) | (2.96) | 0.00 |
| Closing cash | 0.63 | 0.65 | 2.23 | 4.37 | 8.67 | 6.22 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | +16.4% | +15.7% | +3.1% | -20.4% | +85.3% | - |
| EBITDA growth | +95.0% | +578.6% | -66.4% | -82.3% | +131.8% | - |
| PBT growth | -16.9% | +9998.0% | -371.1% | - | +479.3% | +9997.0% |
| Net income growth | +157.0% | +41.7% | -32.1% | -195.8% | +1283.3% | - |
| Revenue CAGR (3Y) | +11.6% | -1.7% | +15.0% | - | - | - |
| EBITDA CAGR (3Y) | +64.5% | -26.1% | -48.3% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +5.6% | +9.0% | -4.6% | -2.2% | +9.2% | +2.0% |
| Return on capital employed | +14.9% | +6.4% | -2.2% | +1.6% | +22.1% | +6.0% |
| Return on net worth | +11.0% | -0.4% | -7.3% | -3.4% | +20.6% | +2.5% |
| Debt / equity | 0.12 | 0.22 | 0.29 | 0.31 | 0.38 | 0.38 |
| Long-term debt / equity | 0.04 | 0.11 | 0.13 | 0.08 | 0.11 | 0.14 |
| Interest cover | 8.26 | 45.91 | -59.06 | -241.76 | 11.76 | 50.14 |
| Efficiency & per share | ||||||
| Fixed asset turnover | 1.17 | 0.95 | 0.79 | 0.84 | 1.33 | 0.84 |
| Inventory turnover | 3.56 | 3.56 | 3.21 | 3.67 | 4.96 | 2.50 |
| Debtors turnover | 5.87 | 5.04 | 5.25 | 6.06 | 8.44 | 4.13 |
| EPS (₹) | 3.98 | 12.70 | (10.62) | (8.05) | 10.12 | (0.67) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 123.59 | 119.49 | 106.85 | 117.28 | 121.17 | 110.08 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.19 | 11.27 | 12.70 | 12.64 | 13.73 | 9.70 | 9.45 | 11.50 |
| Revenue growth (YoY) | -25.8% | +16.2% | +34.4% | +9.9% | +11.7% | - | - | - |
| Other income | 0.07 | 0.02 | 0.00 | 0.53 | 0.04 | 0.03 | 0.57 | 10.19 |
| Total expenses | 10.69 | 11.65 | 11.99 | 12.72 | 13.26 | 10.91 | 10.01 | 11.67 |
| EBITDA | (0.50) | (0.38) | 0.71 | (0.08) | 0.47 | (1.21) | (0.56) | (0.17) |
| EBITDA margin | -4.9% | -3.4% | +5.6% | -0.6% | +3.4% | -12.5% | -5.9% | -1.5% |
| Depreciation | 0.69 | 0.69 | 0.71 | 0.71 | 0.70 | 0.69 | 0.73 | 0.71 |
| Interest | 0.14 | 0.12 | 0.15 | 0.15 | 0.10 | 0.09 | 0.13 | 0.33 |
| Profit before tax | (1.26) | (1.17) | (0.15) | (0.41) | (0.29) | (1.96) | (0.85) | 8.98 |
| Tax | (0.18) | (0.20) | 0.03 | (0.10) | (0.03) | (0.57) | (0.08) | 0.95 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 50.35 | 42.94 | 49.09 | 42.55 | 52.38 | 44.41 | 51.31 |
| Revenue growth | +17.3% | -12.5% | +15.4% | -18.8% | +18.0% | -13.5% | - |
| Other income | 0.59 | 10.92 | 1.15 | 1.14 | 0.85 | 0.41 | 0.23 |
| Total expenses | 49.62 | 45.15 | 52.85 | 46.67 | 49.31 | 41.10 | 48.58 |
| Employee cost | 9.69 | 9.05 | 9.17 | 7.45 | 8.16 | 7.63 | 7.84 |
| EBITDA | 0.73 | (2.21) | (3.76) | (4.12) | 3.07 | 3.31 | 2.73 |
| EBITDA margin | +1.5% | -5.2% | -7.7% | -9.7% | +5.9% | +7.5% | +5.3% |
| Depreciation | 2.80 | 2.85 | 2.71 | 2.40 | 1.91 | 4.20 | 1.99 |
| Interest | 0.53 | 0.94 | 1.63 | 1.38 | 1.68 | 1.60 | 0.70 |
| Profit before tax | (2.01) | 4.92 | (6.95) | (6.76) | 0.33 | (2.08) | 0.27 |
| Tax | (0.29) | 0.29 | 0.00 | (0.41) | 0.14 | (0.46) | 0.37 |
| Net profit | (1.73) | (5.76) | (6.97) | (6.36) | 0.23 | (1.79) | (0.10) |
| Net profit margin | -3.4% | -13.4% | -14.2% | -15.0% | +0.4% | -4.0% | -0.2% |
| EPS (₹) | (2.91) | 7.87 | (11.78) | (10.78) | 0.35 | (3.29) | (0.25) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 5.90 | 5.90 | 5.90 | 5.90 | 4.92 | 4.92 | 4.92 |
| Reserves & surplus | 48.53 | 50.18 | 45.55 | 52.38 | 45.38 | 44.70 | 39.70 |
| Shareholders' funds (net worth) | 54.43 | 56.08 | 51.45 | 58.28 | 50.30 | 49.62 | 44.62 |
| Secured loans | 2.70 | 0.30 | 7.58 | 9.24 | 8.30 | 11.20 | 10.69 |
| Unsecured loans | 1.18 | 1.46 | 7.79 | 1.96 | 11.10 | 4.79 | 2.36 |
| Total debt | 3.88 | 1.76 | 15.37 | 11.20 | 19.40 | 15.99 | 13.05 |
| Total liabilities | 58.58 | 58.00 | 67.99 | 70.69 | 69.90 | 65.83 | 57.85 |
| Assets | |||||||
| Gross block | 45.93 | 45.62 | 56.08 | 54.10 | 41.74 | 40.73 | 38.83 |
| Net block | 26.91 | 29.38 | 39.88 | 40.45 | 29.93 | 30.59 | 32.88 |
| Capital work in progress | 0.06 | 0.04 | 0.00 | 0.04 | 8.94 | 0.12 | 0.69 |
| Investments | 22.60 | 22.59 | 22.56 | 22.52 | 22.55 | 23.66 | 15.04 |
| Inventories | 10.64 | 7.81 | 10.98 | 8.20 | 12.19 | 10.89 | 10.69 |
| Sundry debtors | 5.97 | 5.67 | 6.57 | 7.53 | 5.35 | 7.19 | 7.55 |
| Cash & bank balances | 0.03 | 0.04 | 0.07 | 0.08 | 0.14 | 0.34 | 0.96 |
| Loans & advances | 3.40 | 2.54 | 3.23 | 3.36 | 3.67 | 4.78 | 4.56 |
| Total current assets | 20.04 | 16.06 | 20.85 | 19.17 | 21.35 | 23.20 | 23.76 |
| Total current liabilities | 14.75 | 12.90 | 17.96 | 13.91 | 14.95 | 12.81 | 14.34 |
| Net working capital | 5.29 | 3.16 | 2.89 | 5.26 | 6.40 | 10.39 | 9.42 |
| Total assets | 58.58 | 58.00 | 67.99 | 70.69 | 69.90 | 65.83 | 57.85 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.02 | 0.03 | 0.01 | 0.05 | 0.26 | 0.87 | 2.16 |
| Net cash from operating activities | (2.02) | (1.59) | (3.06) | (1.42) | 6.80 | 0.67 | 4.23 |
| Net cash from investing activities | 0.28 | 16.14 | (2.04) | (3.55) | (8.78) | (2.65) | (8.43) |
| Net cash from financing activities | 1.75 | (14.56) | 5.12 | 4.94 | 1.77 | 1.37 | 2.91 |
| Net change in cash | 0.00 | (0.01) | 0.02 | (0.04) | (0.21) | (0.61) | (1.29) |
| Closing cash | 0.03 | 0.04 | 0.07 | 0.08 | 0.14 | 0.34 | 0.96 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +17.3% | -12.5% | +15.4% | -18.8% | +18.0% | -13.5% | - |
| EBITDA growth | +133.0% | +41.2% | +8.7% | -234.2% | -7.3% | +21.3% | - |
| PBT growth | - | +9998.0% | -2.8% | - | +9998.0% | - | -91.1% |
| Net income growth | +70.0% | +17.4% | -9.6% | -2865.2% | +112.9% | -1690.0% | - |
| Revenue CAGR (3Y) | +5.8% | -6.4% | +3.4% | -6.1% | +4.0% | -7.4% | -4.1% |
| EBITDA CAGR (3Y) | - | - | - | - | +11.4% | -9.1% | -19.4% |
| Profitability & leverage | |||||||
| Net income margin | -3.4% | +10.8% | -14.2% | -14.9% | +0.4% | -3.7% | -0.2% |
| Return on capital employed | -2.5% | -6.7% | -7.7% | -7.7% | +3.0% | -0.8% | +1.8% |
| Return on net worth | -3.1% | -10.7% | -12.7% | -11.7% | +0.4% | -3.4% | -0.3% |
| Debt / equity | 0.05 | 0.16 | 0.24 | 0.28 | 0.35 | 0.31 | 0.23 |
| Long-term debt / equity | 0.02 | 0.08 | 0.11 | 0.08 | 0.12 | 0.17 | 0.16 |
| Interest cover | -25.60 | -18.58 | -25.19 | -21.17 | 144.83 | -179.78 | 94.59 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.10 | 0.84 | 0.89 | 0.89 | 1.27 | 1.12 | 1.69 |
| Inventory turnover | 5.46 | 4.57 | 5.12 | 4.17 | 4.54 | 4.12 | 4.60 |
| Debtors turnover | 8.65 | 7.02 | 6.96 | 6.61 | 8.35 | 6.03 | 8.18 |
| EPS (₹) | (2.91) | 7.87 | (11.78) | (10.78) | 0.35 | (3.29) | (0.25) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 92.25 | 95.04 | 87.19 | 98.78 | 102.30 | 100.92 | 90.74 |
Web traffic of Makers Laboratories
The website of Makers Laboratories (makerslabs.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▲ 18.5% vs previous month
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Makers Laboratories (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 89.42 M | 962 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | USD 508.93 M | 5,180 | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | USD 6.21 B | 25,870 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Makers Laboratories
Complete news archive for Makers Laboratories
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Makers Laboratories
Makers Laboratories was founded in 1985.
Makers Laboratories is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Makers Laboratories has 131 employees.
The primary company behind Makers Laboratories, Makers Laboratories Ltd, reported revenue of ₹142 Cr for FY 2026, up 16% year on year.
Manufacturer of branded generic pharmaceutical products. It offers a portfolio covering various therapeutic segments, including antibiotics, cough and cold medications, cardio-diabetic treatments, anti-allergics, anthelmintics, and neurotonics. The company focuses on providing high-quality products at affordable prices. Its product line includes formulations such as paracetamol, arteether, chloroquine, nimuselide, and amoxycillin.
Makers Laboratories offers Duramol and Artemak-AB.
Yes, Makers Laboratories is publicly traded on BSE under the ticker symbol MAKERSL.
Makers Laboratories operates through Makers Laboratories Ltd.
The legal entities of Makers Laboratories currently have 8 directors, including Raj Kamal Prasad Verma, Prashant Godha, Vishal Babulal Jain and others.